Reporting of Clinical Adverse Events Scale: a measure of doctor and nurse attitudes to adverse event reporting

被引:34
|
作者
Wilson, B. [1 ]
Bekker, H. L. [2 ]
Fylan, F. [3 ]
机构
[1] Univ York, Dept Hlth Sci, York YO10 5DD, N Yorkshire, England
[2] Univ Leeds, Sch Med, Inst Hlth Sci & Publ Hlth Res, Leeds LS2 9JT, W Yorkshire, England
[3] Leeds Metropolitan Univ, Dept Psychol, Sch Hlth & Human Sci, Leeds LS1 3HE, W Yorkshire, England
来源
QUALITY & SAFETY IN HEALTH CARE | 2008年 / 17卷 / 05期
关键词
D O I
10.1136/qshc.2006.021691
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objective: To develop a validated measure of professionals' attitudes towards clinical adverse event reporting (CAER). Design: Cross-sectional survey with follow-up. Participants: 201 doctors and nurse/nurse-midwives undergoing postqualification training in Leeds, York and Hull Universities in 2003. Materials: A questionnaire which comprised 73 items extracted from interviews with professionals; a second, statistically reduced version of this questionnaire. Results: The analysis supported a 25-item questionnaire comprising five factors: blame as a consequence of reporting (six items); criteria for reporting (six items); colleagues' expectations (six items); perceived benefits of reporting events (five items); and clarity of reporting procedures (two items). The resulting questionnaire, the Reporting of Clinical Adverse Effects Scale (RoCAES), had satisfactory internal consistency (Cronbach's alpha = 0.83) and external reliability (Spearman's correlation = 0.65). The construct validity hypothesis -doctors have less positive attitudes towards CAER than nurses -was supported (t = 5.495; p < 0.0001). Conclusion: Initial development of an evidence-based, psychometrically rigorous measure of attitudes towards CAER has been reported. Following additional testing, RoCAES may be used to systematically elicit professionals' views about, and inform interventions to improve, reporting behaviour.
引用
收藏
页码:364 / 367
页数:4
相关论文
共 50 条
  • [1] Reporting adverse events: Greek doctor and nurse attitudes
    Moumtzoglou, Anastasius
    [J]. INTERNATIONAL JOURNAL OF HEALTH CARE QUALITY ASSURANCE, 2010, 23 (07) : 680 - +
  • [2] Adverse events and adverse event reporting systems
    Huebler, M.
    Moellemann, A.
    Metzler, H.
    Koch, T.
    [J]. ANAESTHESIST, 2007, 56 (10): : 1067 - +
  • [3] Suboptimal reporting of adverse medical events to the FDA Adverse Events Reporting System by nurse practitioners and physician assistants
    Ehrenpreis, Eli D.
    Sifuentes, Humberto
    Ehrenpreis, Jamie E.
    Smith, Zachary L.
    Marshall, Mike L.
    [J]. EXPERT OPINION ON DRUG SAFETY, 2012, 11 (02) : 177 - 183
  • [4] Anaesthetists' attitudes to adverse incident reporting - Evaluation of a reporting scale
    Sacks, M.
    Smith, S.
    Sevdalis, N.
    [J]. EUROPEAN JOURNAL OF ANAESTHESIOLOGY, 2010, 27 (01) : 231 - 231
  • [5] Preventing and Reporting Adverse Drug Events Pharmacovigilance for the Clinical Nurse Specialist
    O'Malley, Patricia Anne
    [J]. CLINICAL NURSE SPECIALIST, 2012, 26 (03) : 136 - 137
  • [6] Reporting adverse events at geriatric facilities Categorization by type of adverse event and function of reporting personnel
    Shmueli, Tali
    Noy, Ronit Har
    Ben Natan, Merav
    Ben-Israel, Joshua
    [J]. INTERNATIONAL JOURNAL OF HEALTH CARE QUALITY ASSURANCE, 2014, 27 (02) : 91 - +
  • [7] Advantages and Limitations of the Federal Adverse Events Reporting System in Assessing Adverse Event Reporting for Eluxadoline
    Chedid, Victor
    Vijayvargiya, Priya
    Camilleri, Michael
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2018, 16 (03) : 336 - 338
  • [8] Adverse event reporting
    Kruft, Bonnie
    Nelson, Lindsay A.
    Stewart, Jeanette A.
    Stewart, William C.
    [J]. OPHTHALMOLOGY, 2007, 114 (07) : 1420 - 1420
  • [9] Vedolizumab Adverse Events: Analysis of the FDA Adverse Event Reporting System
    Jow, Steven
    Hutfless, Susan
    [J]. INFLAMMATORY BOWEL DISEASES, 2017, 23 : S35 - S36
  • [10] Adverse Events Reporting
    K. Higuchi
    [J]. Clinical Drug Investigation, 2007, 27 : 225 - 225